8-K: Cardiff Oncology Reports Positive Trial Data, Extends Cash Runway

Cardiff Oncology announced encouraging Phase 2 trial results for onvansertib in RAS-mutated metastatic colorectal cancer and extended its cash runway into Q1 2027.

Summary

• Reported positive data from the ongoing Phase 2 CRDF-004 trial for onvansertib in combination with standard of care for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• The 30mg onvansertib arm showed a 19% improvement in confirmed objective response rate (ORR) compared to the control arm as of July 8, 2025.
• Early progression-free survival (PFS) data indicate a trend favoring the 30mg onvansertib arm, with median PFS not yet reached.
• Onvansertib demonstrated dose-dependent responses across all endpoints and maintained a favorable tolerability profile with no major or unexpected toxicities.
• Cash, cash equivalents, and short-term investments totaled $60.6 million as of September 30, 2025.
• The company projects its current cash resources are sufficient to fund operations into Q1 2027.
• Net loss for Q3 2025 was $11.3 million, an improvement from $11.9 million in Q3 2024.
• Total operating expenses decreased to $12.1 million in Q3 2025 from $12.8 million in Q3 2024, primarily due to reduced clinical trial and preclinical activities.

Sentiment

Score: 8

Explanation: The positive Phase 2 data for onvansertib in a challenging cancer indication (RAS-mutated mCRC) is a significant de-risking event. Combined with an extended cash runway and improved financial metrics (reduced net loss and operating expenses), the overall sentiment is highly positive, indicating progress and increased confidence in the company's lead asset.

Positives

• Positive data from Phase 2 CRDF-004 trial, showing a 19% improvement in confirmed ORR for the 30mg onvansertib arm in RAS-mutated mCRC.
• Early signs of separation in progression-free survival (PFS) curves favoring the treatment arm.
• Onvansertib continues to be well-tolerated with no major or unexpected toxicities.
• Cash and investments of $60.6 million provide a projected cash runway into Q1 2027.
• Net loss decreased to $11.3 million in Q3 2025 from $11.9 million in Q3 2024.
• Total operating expenses decreased by $0.7 million in Q3 2025 compared to Q3 2024.

Negatives

• Net cash used in operating activities increased slightly to $10.8 million in Q3 2025 from $10.5 million in Q3 2024.
• Weighted-average shares outstanding significantly increased to 66,879 thousand in Q3 2025 from 46,865 thousand in Q3 2024, indicating substantial dilution.

Risks

• Clinical trials are lengthy, expensive, and have uncertain outcomes, and earlier results may not predict future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
• Results of preclinical studies or clinical trials could be unfavorable or delayed.
• The company may need additional financing in the future.
• Risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks.
• Uncertainties regarding government or third-party payer reimbursement.
• Dependence on key personnel.
• Limited experience in marketing and sales.
• Substantial competition in the oncology drug development space.
• Uncertainties of patent protection and litigation.
• Dependence upon third parties for various aspects of development and operations.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• No guarantees that the product candidate will be utilized or prove to be commercially successful.
• No guarantees that future clinical trials will be completed or successful or that the product candidate will receive regulatory approval for any indication.

Future Outlook

Cardiff Oncology expects to report the next clinical update from the Phase 2 CRDF-004 trial in the first quarter of 2026, focusing on more mature duration of response and progression-free survival data. The company projects its current cash resources will fund operations into Q1 2027.

Management Comments

• "This quarter was marked by highly encouraging data from our ongoing CRDF-004 trial evaluating onvansertib in combination with standard of care for first-line RAS-mutated mCRC."
• "The study is on track for the next clinical update in the first quarter of 2026, where we'll look for a continuation of onvansertib's favorable tolerability profile and more mature duration of response and progression-free survival data."
• "Onvansertib is uniquely positioned to address a significant medical need and commercial opportunity, with approximately 150,000 new CRC patients diagnosed annually in the U.S. alone."
• "With median progression-free survival of less than 12 months on standard of care and few promising therapies in development for RAS-mutated mCRC, we are optimistic that onvansertib has the potential to redefine first-line care for patients."

Industry Context

The positive Phase 2 data for onvansertib in RAS-mutated mCRC addresses a significant unmet medical need, as current standard of care offers median progression-free survival of less than 12 months and few promising alternative therapies are in development for this specific patient population. The market for colorectal cancer therapies, particularly for RAS-mutated forms, represents a substantial commercial opportunity given the high incidence rate in the U.S. alone.

Stakeholder Impact

• Shareholders: Positive clinical trial data and extended cash runway could lead to increased investor confidence and potential share price appreciation. However, past dilution (indicated by increased shares outstanding) is a consideration.
• Patients (RAS-mutated mCRC): The positive trial results offer hope for a new, more effective treatment option for a cancer with significant unmet medical need.
• Employees: Continued progress in clinical trials and financial stability provide job security and positive momentum.
• Regulatory Authorities: Positive data will be crucial for future discussions and potential regulatory submissions.

Next Steps

• Report an update from the Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC in Q1 2026.
• Continue evaluating onvansertib in ongoing and planned investigator-initiated trials in mPDAC, SCLC, and mTNBC.

Key Dates

Recommendation

The positive Phase 2 data for onvansertib in RAS-mutated mCRC represents a significant clinical de-risking event for Cardiff Oncology's lead asset. A 19% improvement in ORR, coupled with early PFS separation and a favorable tolerability profile, suggests a potentially transformative therapy in an area with high unmet medical need and limited treatment options. The extended cash runway into Q1 2027 provides a solid financial foundation to advance the program without immediate dilution concerns. While the company is still clinical-stage and faces inherent risks, this data significantly increases the probability of success for onvansertib and positions the company favorably for future development and potential partnerships. The improved financial performance (reduced net loss and operating expenses) further supports a positive outlook.

Keywords

Cardiff Oncology, CRDF, Onvansertib, PLK1 inhibitor, RAS-mutated mCRC, Colorectal Cancer, Metastatic Cancer, Phase 2 Trial, Clinical Data, Biotechnology, Oncology, Drug Development, Financial Results, Cash Runway, Q3 2025